Womens Health Investment Outlook 2026

The data in the index paints a more detailed picture of where and how capital is flowing into women’s health – and which areas continue to be underserved. It reveals a market still constrained by early-stage concentration, persistent underfunding of women-specific conditions and a lack of sex-specific strategies in high-burden conditions that affect women differently and disproportionately. At the same time, new patterns are emerging: horizontal business models, diversified players and geographic gaps that, if addressed, could define the next frontier of investable opportunity.2.1 The investment gap in women’s health Private-sector financing events in healthcare (2020–2025) FIGURE 4 Source: Pitchbook, CapIQ, Crunchbase, Boston Consulting GroupWomen’s health received 6% of all private-sector funding ($175 billion ) Women’s health-specific health companies received less than 1% of all private-sector funding ($23 billion )$2.87 trillion Total healthcar e private-sector funding A fragmented, early-stage market Most private investments in women’s health remain concentrated in early development, particularly for women’s health-specific companies. Between 2020 and 2025, 50% of identified private investments in women’s health-specific companies were at the pre-seed or seed stage, 22% at early stage and 28% at later stage. In contrast, private investment into the broader healthcare sector shows a more even distribution, with 32% at pre-seed or seed, 27% at early stage and 41% at later stage. Overall, investment in women’s health-specific companies remains roughly 18 percentage points more skewed towards early-stage investment. Additional analyses found that although women’s health investment remains heavily weighted towards early-stage funding, median company ages are roughly on par with the broader health market across all funding stages. From pre-seed to later rounds, women’s health companies are not “younger” than the broader healthcare market (see Appendix B, Figure 17). This suggests that the challenge may lie in the ability of women’s health innovations to progress beyond early validation. The hypothesis for this report is that women’s health faces a “leaky pipeline” in scaling innovation, where promising discoveries, particularly from academia and early research, struggle to attract venture capital or growth funding. With few later-stage opportunities currently visible, capital has gravitated towards early validation and proof-of-concept rounds, potentially reinforcing fragmentation and limiting pathways to scale. Whether this pattern reflects a shortage of scale-ready assets, a lack of investor appetite or structural barriers (such as regulatory uncertainty, reimbursement gaps, evidence and innovation not aligning with investor demand, and constrained access to growth capital), the outcome is the same: a market where early innovation outweighs later-stage scale. This dynamic presents a clear opportunity for targeted engagement and growth capital to help bridge the gap and unlock the next phase of market maturity. Women’s Health Investment Outlook 13